Search results for "amp"

showing 10 items of 10184 documents

Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma

2010

Patients with advanced pancreatic cancer failing gemcitabine-based first-line chemotherapy are still in relatively good clinical conditions and may still require second-line chemotherapy, which is frequently administered in daily clinical practice given to without solid scientific support.A retrospective survey was carried out including 40 patients with stage III or IV gemcitabine-refractory pancreatic carcinoma. Patients received standard FOLFIRI regimen biweekly until progression or unacceptable toxicity. Response evaluation criteria in solid tumors and National Cancer Institute common toxicity criteria were employed respectively for response and toxicity assessment.Six partial responses …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentLeucovorinIrinotecanBolus (medicine)Pancreatic cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineFOLFIRI RegimenHumansPancreatic carcinomaAgedRetrospective StudiesChemotherapybusiness.industryMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabinePancreatic NeoplasmsIrinotecanOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

Irinotecan (CPT-11) and Mitomycin-C (MMC) as Second-Line Therapy in Advanced Gastric Cancer

2005

Objective The aim of this study was to evaluate the activity and toxicity of a combination regimen of CPT-11 and mitomycin-c as second-line chemotherapy for pretreated patients with advanced, metastatic, or both, gastric adenocarcinoma. Materials and methods Patients with pretreated metastatic disease or early relapsed after adjuvant chemotherapy were enrolled. Entry criteria included histologic/cytologic diagnosis of gastric adenocarcinoma, age 18 to 75 years, performance status > or =70 (Karnofsky scale), bi-dimensionally measurable disease. Patients received CPT-11 and mitomycin-c at the dosage of 150 mg/m2 on days 1 and 15, and 8 mg/m2 on day 1, respectively, every 4 weeks. The disease …

AdultMaleOncologyCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaMitomycinmedicine.medical_treatmentSalvage therapyPhases of clinical researchAdenocarcinomaNeutropeniaIrinotecanGastroenterologyDisease-Free SurvivalStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansLife TablesPeritoneal NeoplasmsAgedSalvage TherapyChemotherapyLeukopeniaPerformance statusbusiness.industryLiver NeoplasmsDrug SynergismMiddle Agedmedicine.diseaseSurvival Analysistherapy gastric cancerIrinotecanRegimenTreatment OutcomeItalyOncologyLymphatic MetastasisCamptothecinFemalemedicine.symptombusinessmedicine.drugAmerican Journal of Clinical Oncology
researchProduct

FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer

2014

<b><i>Purpose:</i></b> Fluoropyrimidines, oxaliplatin, irinotecan and targeted therapies represent the standard treatment of metastatic colorectal cancer. After failure of all these treatments, few options are available. In such chemorefractory patients the effect of triplet chemotherapy with bevacizumab (FOLFIRINOX bevacizumab) has never been investigated. <b><i>Patients and Methods:</i></b> 49 consecutive patients bearing unresectable metastatic colorectal cancer and who experienced failure to oxaliplatin- and irinotecan-based chemotherapy were treated with oxaliplatin (85 mg/m<sup>2</sup>), irinotecan (180 mg/m<sup>2</s…

AdultMaleOncologyCancer Researchmedicine.medical_specialtyOrganoplatinum CompoundsBevacizumabFOLFIRINOXColorectal cancerLeucovorinSalvage therapyAntibodies Monoclonal HumanizedIrinotecanInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesSurvival rateAgedNeoplasm StagingAged 80 and overSalvage Therapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle AgedPrognosismedicine.diseasedigestive system diseasesOxaliplatinBevacizumabOxaliplatinSurvival RateIrinotecanOncologyDrug Resistance NeoplasmFluorouracilCamptothecinFemaleFluorouracilColorectal NeoplasmsbusinessFollow-Up Studiesmedicine.drugOncology
researchProduct

High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability.

2007

Mutation screening of the BRCA1 and BRCA2 genes in probands with familial breast/ovarian cancer has been greatly improved by the multiplex ligation-dependent probe amplification (MLPA) assay able to evidence gene rearrangements not detectable by standard screening methods. However, no criteria for selection of cases to be submitted to the MLPA test have been reported yet. We used the BRCAPro software for the selection of familial breast/ovarian cancer probands investigated with the MLPA approach after negative BRCA1/2 conventional mutation screening. One hundred and seventy-seven probands were investigated for germline BRCA1/2 mutations after assessment of genetic risk using BRCAPro. Proban…

AdultMaleOncologyProbandcongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyendocrine system diseasesBreast NeoplasmsGermlineBreast Neoplasms MaleGermline mutationBreast cancerRisk FactorsInternal medicinePrevalenceHumansMedicineGenetic Predisposition to DiseaseMultiplexMultiplex ligation-dependent probe amplificationskin and connective tissue diseasesAgedSequence DeletionOvarian NeoplasmsGeneticsBRCA1 Proteinbusiness.industryGenetic Carrier ScreeningProstatic NeoplasmsHematologyMiddle Agedmedicine.diseaseBRCA1 BRCA2 BRCAPro breast cancer MLPA ovarian cancerPedigreeOncologyMutation (genetic algorithm)FemalebusinessOvarian cancerSoftware
researchProduct

Final results from a randomized phase 3 study of FOLFIRI \pm$ panitumumab for second-line treatment of metastatic colorectal cancer

2013

Abstract: Background: The study 20050181 demonstrated significant improvements in progression-free survival (PFS), objective response, and a nonsignificant trend toward increased overall survival (OS) with panitumumab-FOLFIRI versus FOLFIRI alone for second-line wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Updated long-term data from a prespecified descriptive analysis are reported. Patients and methods: Patients receiving one prior mCRC treatment were randomly assigned (1:1) to panitumumab (6.0 mg/kg)-FOLFIRI versus FOLFIRI every 2 weeks. Co-primary end points (PFS and OS) were prospectively analyzed by tumor KRAS status. Results: One thousand one hundred and eighty-six patient…

AdultMaleOncologymedicine.medical_specialtyBevacizumabColorectal cancerLeucovorinPhases of clinical researchKaplan-Meier Estimatemedicine.disease_causeSkin DiseasesDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPanitumumabProgression-free survivalAgedAged 80 and overbusiness.industryPanitumumabLiver NeoplasmsHazard ratioAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseTreatment OutcomeOncologyQuality of LifeFOLFIRICamptothecinFemaleFluorouracilKRASHuman medicineColorectal Neoplasmsbusinessmedicine.drugAnnals of oncology
researchProduct

Efficacy and Safety of Cetuximab/Irinotecan in Chemotherapy-Refractory Metastatic Colorectal Adenocarcinomas: A Clinical Practice Setting, Multicente…

2006

This study was designed to evaluate the efficacy and safety of irinotecan/cetuximab administered as third- or fourth-line therapy in a retrospective series of patients with metastatic colorectal cancer refractory to oxaliplatin and irinotecan. Patients and Methods: Most patients (90%) had been previously treated with adjuvant 5-fluorouracil/leucovorin, and all had received oxaliplatin-based regimens before receiving irinotecan- based second-line treatment. Sixty patients with irinotecan-refractory colorectal cancer received a regimen comprising weekly irinotecan 120 mg/m 2 as a 1-hour intravenous infusion and cetuximab 400 mg/m 2 infused over 2 hours as the initial dose and 250 mg/m 2 infus…

AdultMaleOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsSettore MED/06 - Oncologia MedicaColorectal cancermedicine.medical_treatmentCetuximabAdenocarcinomaAntibodies Monoclonal HumanizedIrinotecanDisease-Free SurvivalInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansNeoplasm MetastasisSurvival analysisAgedAged 80 and overChemotherapyCetuximabPerformance statusbusiness.industryGastroenterologyAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseasesOxaliplatinErbB ReceptorsIrinotecanSettore MED/18 - Chirurgia GeneraleRegimenOncologyCamptothecinFemaleEpidermal growth factor receptor Oxaliplatin Vascular endothelial growth factorColorectal Neoplasmsbusinessmedicine.drugClinical Colorectal Cancer
researchProduct

Association of functional DBH genetic variants with alcohol dependence risk and related depression and suicide attempt phenotypes: Results from a lar…

2012

Abstract Objective Dopamine-beta-hydroxylase (DBH) metabolizes the conversion of dopamine to noradrenaline. DBH, located on chromosome 9q34.2 has variants with potential functional consequences which may be related to alterations of neurotransmitter function and several psychiatric phenotypes, including alcohol dependence (AD), depression (MD) and suicidal behavior (SA). The aim of this association study in a large multicenter sample of alcohol-dependent individuals and controls is to investigate the role of DBH SNPs and haplotypes in AD risk and associated phenotypes (AD with MD or SA). Method 1606 inpatient subjects with DSM-IV AD from four addiction treatment centers and 1866 control sub…

AdultMaleOncologymedicine.medical_specialtyGenotypePoison controlSuicide AttemptedSingle-nucleotide polymorphismDopamine beta-HydroxylaseToxicologyPolymorphism Single NucleotideRisk AssessmentLinkage DisequilibriumGermanyInternal medicinemedicineHumansSNPPharmacology (medical)Age of OnsetDepression (differential diagnoses)PharmacologyDepressive DisorderSex CharacteristicsSuicide attemptAlcohol dependenceHaplotypeDNAMiddle AgedAlcoholismPsychiatry and Mental healthPhenotypeCase-Control StudiesSample SizeEtiologyFemalePsychologyGenome-Wide Association StudyClinical psychologyDrug and Alcohol Dependence
researchProduct

Determinants of dental care utilization by the adult population in Buenos Aires

2008

Objective: To establish the frequency with which the general population is seen by a dentist and the variables associated with the lack of regular dental check-ups. Methods: A cross-sectional study with a descriptive and analytical phase conducted in an urban community in Argentina. A sample population was obtained by stratified method. Socioeconomic conditions (measure by UBN index), health, health coverage, level of education and location of the households with respect to the dental clinics were all taken into consideration in selecting the sample. We performed a uni-and multivariate analysis. The statistical software used was SPSS 9.0 for Windows and Epilnfo6 Version 6.0. Results: We obs…

AdultMaleOral healthMultivariate analysisAdolescentUrban Populationmedia_common.quotation_subjectPopulationArgentinaSample (statistics)DentistYoung AdultPromotion (rank)Environmental healthStatistical significanceHumansPromotionMedicineProspective StudiesDental CareeducationPovertyGeneral DentistrySocioeconomic statusAgedmedia_commoneducation.field_of_studyPovertybusiness.industryPreventionRegression analysisMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Cross-Sectional StudiesOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASCiencias MédicasFemaleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Effectiveness of lingual versus labial fixed appliances in adults according to the Peer Assessment Rating index.

2019

Introduction: The purpose of this study was to compare the effectiveness of lingual treatment and labial fixed appliances in the treatment of adult orthodontic patients. Methods: We conducted a retrospective study of 72 patients. The Peer Assessment Rating (PAR) index was measured at the start (T0) and end (T1) of treatment. Significant differences between treatment means were determined by means of analysis of variancewith the Bonferroni correction or with the use of Fisher exact test. Results: The lingual group had a mean pretreatment age of 28.6 ± 6.7 years, and the labial group had a pretreatment age of 26.6 ± 9.5 years. This difference was statistically not significant. The mean pre- a…

AdultMaleOrthodontic Appliances FixedTreatment outcomeInvestigación médicaOdontologíaOrthodontics03 medical and health sciencessymbols.namesake0302 clinical medicinestomatognathic systemMedicineHumansOrthodontic Appliance DesignAparatos ortodóncicos fijosFisher's exact testRetrospective StudiesOrthodonticsbusiness.industryRetrospective cohort study030206 dentistryPeer Review Health CareOrtodonciastomatognathic diseasesBonferroni correctionTreatment OutcomeSample size determinationsymbolsFemalebusiness030217 neurology & neurosurgeryAmerican journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics
researchProduct

Cerebral activation in patients with somatoform pain disorder exposed to pain and stress: an fMRI study.

2006

Patients with somatoform pain disorders are supposed to suffer from an early acquired defect in stress regulation. In order to look for common alterations of the pain- and stress-responsive cortical areas, we prospectively recorded cerebral activations induced by pin-prick pain, by cognitive stress and emotional stress using functional magnetic resonance imaging (fMRI) in a group of 17 patients and an age-matched control group. In addition, the hippocampal volumes of both groups were measured. Patients showed increased activations of the known pain-processing areas (thalamus, basal ganglia, operculo-insular cortex), but also of some prefrontal, temporal and parietal regions during first pai…

AdultMalePain ThresholdCognitive NeuroscienceThalamusAction PotentialsPainHippocampal formationSomatosensory systemSuperior temporal gyrusStress PhysiologicalEvoked Potentials SomatosensoryBasal gangliaThreshold of painmedicineHumansSomatoform DisordersBrain Mappingmedicine.diagnostic_testBrainMiddle AgedAnticipationMagnetic Resonance ImagingNeurologyFemaleFunctional magnetic resonance imagingPsychologyNeuroscienceNeuroImage
researchProduct